
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES
EXCHANGE ACT OF 1934**

Date of Report: September 11, 2026

Commission File Number: 001-36891

Collectis S.A.
(Exact Name of registrant as specified in its charter)

**8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

<u>Exhibit</u>	<u>Title</u>
<u>99.1</u>	<u>Press Release, dated September 11, 2026</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Collectis S.A.

(Registrant)

Date: September 11, 2026

/s/ André Choulika

André Choulika
Chief Executive Officer

Collectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Collectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update.

Conference Call and Webcast Details:

September 14, 2026

- **English-language at 8:00 a.m. ET. / 2:00 p.m. CET**

Webcast link:

https://viaid.webcasts.com/starthere.jsp?ei=1775356&tp_key=7d1d05c480

Phone number: +1 (800) 717 1738 or +1 (646) 307 1865

France Toll Free: +33 (800) 945 120

- **French-language at 9:00 a.m. ET. / 3:00 p.m. CET**

Webcast link:

https://viaid.webcasts.com/starthere.jsp?ei=1775361&tp_key=2968b7b0ca

Phone number: +1 (800) 717 1738 or +1 (646) 307 1865

France Toll Free: +33 (800) 945 120

A replay will be available on the [Company's website](#) following the event.

About Collectis

Collectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Collectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Collectis' headquarters are in Paris, France, with locations in New York and Raleigh, NC. Collectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.collectis.com and follow Collectis on LinkedIn and X.

For further information on Collectis, please contact:

Media contacts:

Pascalyné Wilson, Director, Communications, + 33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, media@collectis.com

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@collectis.com

Attachment

- PRESS RELEASE_conference call_ENGLISH (<https://ml.globenewswire.com/Resource/Download/0b5bb3dc-fd34-48a8-ab2a-a13f19bdae7f>)